Friday, January 25, 2013

Partnerships Session Spotlight: Strategies to Create More Value When Contracting with CROs

This April at Partnerships in Clinical Trials, we're taking a look at how Pharma companies can look at the new effective way to partner throughtout a trial and focus on the long term goals while focusing on cost savings and value throughout a campaign. As clinical trial costs continue to climb, identifying areas of savings while demanding more accountability from your providers is more challenging than ever before. Clinical Trial Sponsors are moving away from focusing on the bottom line price during negotiations and look towards added value to their outsourcing options. Partnerships in Clinical Trials 2013 provides you with an educational platform to make the most of your clinical trial dollars in the featured session Strategies to Create More Value When Contracting with CROs.

Leaner Clinical
Trials
For more information on this session and the rest of the event, download the agenda. If you'd like to join us this April 21-24, 2013 in Orlando, Florida, as a reader of this blog when you register to join us and mention code XP1800BLOG, you save 15% off the standard rate.

Featured Session: Strategies to Create More Value When Contracting with CROs

Featured participants: Suresh Kannan, VP Products, Clinical Trial Optimization Solutions, IMS Health
Lynn Newbould, Senior Director Clinical Outsourcing and Contracts Management, Molecular Insight Pharmaceuticals, Inc.
Julia Love, Senior Consultant, Clinical Outsourcing, Millennium Pharmaceuticals, Inc.

About the session: There is a steady shift in the industry for sponsors to demand more accountability as outsourcing strategy goes beyond cost savings and into demonstrating value. Trial sponsors expect their CRO partners to very clearly state what they are going to do and how they are going to do it and then follow through while maintaining quality and staying within budget. However, the industry is still struggling to find an effective process that can engage stakeholders and still be streamlined.
• How do we move the industry away from focusing on the bottom line price during negotiations and look towards the cost effectiveness and “added value” of the outsourcing option?
• What creative solutions are there when CROs are being utilized far earlier in the process than ever before?




No comments: